Review3 Biotech2025
Innovation landscape in nanobiosensors for COVID-19 detection and future implications for a resilient Global Health Security.
Review in 3 Biotech, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This review presents a comprehensive analysis of nanobiosensors (NBSs) advancements for COVID-19 detection, highlighting their repurposing potential to enhance global health security against emerging threats. It outlines the use of various nanomaterials like gold and magnetic nanoparticles in developing NBSs for detecting SARS-CoV-2, emphasizing their adaptability and rapid detection capabilities. Gold nanoparticles are highlighted for their superior surface chemistries and stability, making them ideal for label-free COVID-19 detection and other diagnostic applications. Magnetic nanoparticles, particularly superparamagnetic iron oxides, offer alternative detection mechanisms based on magnetism, providing high sensitivity and reliability in pathogen detection. The document also discusses nonmetallic nanomaterials, such as single-walled carbon nanotubes and selenium nanoparticles, which have been used to develop optical and electrochemical NBSs for COVID-19 detection. Breathalyzers are recognized for their noninvasive, rapid detection of volatile organic compounds specific to COVID-19. Such advancements in NBSs have significantly contributed to global health security by providing reliable, portable, and affordable diagnostic solutions, especially in resource-limited settings. However, despite technological advancements, commercialization and market adoption challenges persist, necessitating improvements in manufacturing scalability, cost reduction, and clinical validation. The document emphasizes the need for transparent and efficient regulatory strategies to address concerns related to nanomaterial toxicity, health effects, and environmental impact during the R&D phase. While presenting a comprehensive framework for successful research to market translation, this review highlights the need for cross-sectoral collaboration to tailor country-specific nanotechnology roadmaps for optimized resource allocation, navigating diverse regulations, and addressing unique societal needs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.